Apixaban vs Rivaroxaban — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Factor Xa Inhibitor

Apixaban

Brand: ELIQUIS

First FDA approval: 2012-12-28

Factor Xa Inhibitor

Rivaroxaban

Brand: XARELTO

First FDA approval: 2011-07-01

Lowest NADACAcquisition cost floor across all NDCs

$5.51Per unit

$0.979Per unit

Average NADACAcross all dosage forms and strengths

$5.52Up to $5.53

$7.68Up to $19.56

Generic manufacturersActive ANDA holders — FDA Orange Book

24 total ANDAs filed

1758 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$32.24BFull year

$9.48BFull year

Part D claims (CY24)Total fills, all strengths

36.8M8.4M beneficiaries

10.0M2.5M beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$875Per claim, all NDCs

$951Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

0Zero PA friction

1Minimal friction

Step therapy appliedPlan-NDC pairs requiring step therapy

18Limited friction

62Limited friction

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

Generic availableFDA Orange Book

Yes2 manufacturers

Yes17 manufacturers